Etzer Darout

Stock Analyst at Barclays

(3.58)
# 872
Out of 5,045 analysts
132
Total ratings
46.46%
Success rate
7.65%
Average return

Stocks Rated by Etzer Darout

Xencor
Oct 29, 2025
Upgrades: Overweight
Price Target: $6$23
Current: $14.67
Upside: +56.78%
Terns Pharmaceuticals
Oct 22, 2025
Maintains: Overweight
Price Target: $15$14
Current: $8.02
Upside: +74.56%
Summit Therapeutics
Oct 21, 2025
Maintains: Underweight
Price Target: $13$16
Current: $18.66
Upside: -14.26%
RAPT Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $35$58
Current: $29.78
Upside: +94.76%
CytomX Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5$6
Current: $3.26
Upside: +84.05%
Celldex Therapeutics
Oct 13, 2025
Initiates: Underweight
Price Target: $25
Current: $25.99
Upside: -3.81%
Tvardi Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.78
Upside: +1,176.15%
Oruka Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $27.61
Upside: +73.85%
Monopar Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $84.16
Upside: +48.54%
Corvus Pharmaceuticals
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $7.68
Upside: +108.33%
Initiates: Overweight
Price Target: $78
Current: $36.12
Upside: +115.95%
Initiates: Overweight
Price Target: $142
Current: $98.94
Upside: +43.52%
Downgrades: Equal-Weight
Price Target: $112$97
Current: $94.81
Upside: +2.31%
Maintains: Overweight
Price Target: $45$44
Current: $29.27
Upside: +50.32%
Maintains: Overweight
Price Target: $8$10
Current: $2.51
Upside: +298.41%
Assumes: Overweight
Price Target: $3
Current: $1.69
Upside: +77.51%
Initiates: Equal-Weight
Price Target: $40
Current: $39.43
Upside: +1.45%
Assumes: Overweight
Price Target: $16
Current: $9.59
Upside: +66.84%
Initiates: Overweight
Price Target: $72
Current: $76.69
Upside: -6.12%
Initiates: Overweight
Price Target: $60
Current: $60.03
Upside: -0.05%
Initiates: Overweight
Price Target: $47
Current: $27.81
Upside: +69.00%
Maintains: Buy
Price Target: $9$13
Current: $4.16
Upside: +212.50%
Maintains: Outperform
Price Target: $130$143
Current: $103.35
Upside: +38.36%
Downgrades: Market Perform
Price Target: $22$3
Current: $2.68
Upside: +11.94%
Initiates: Outperform
Price Target: $35
Current: $11.70
Upside: +199.15%
Initiates: Outperform
Price Target: $63
Current: $2.36
Upside: +2,569.49%
Maintains: Outperform
Price Target: $28$27
Current: $1.89
Upside: +1,328.57%
Maintains: Outperform
Price Target: $132$134
Current: $102.97
Upside: +30.13%
Reiterates: Outperform
Price Target: $46$48
Current: $28.95
Upside: +65.80%
Maintains: Market Perform
Price Target: $118$120
Current: $121.80
Upside: -1.48%
Maintains: Market Perform
Price Target: $7$6
Current: $1.34
Upside: +347.76%
Maintains: Outperform
Price Target: $80$82
Current: $82.23
Upside: -0.28%
Maintains: Outperform
Price Target: $20$19
Current: $4.23
Upside: +349.17%
Upgrades: Buy
Price Target: $170
Current: $481.59
Upside: -64.70%
Initiates: Buy
Price Target: $54
Current: $54.00
Upside: -
Maintains: Buy
Price Target: $27$38
Current: $70.46
Upside: -46.07%
Maintains: Outperform
Price Target: $54$52
Current: $2.34
Upside: +2,122.22%